单克隆抗体配方:对市场上的产品和专利进行定量分析
Yixuan Peng1, Liyang Lyu1, Shiyun Chen1
1State Key Laboratory of Mechanism and Quality of Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao SAR, China.
mAbs
|October 30, 2025
概括
单克隆抗体 (mAb) 配方趋势显示出基于度和施用途径的特定辅助剂偏好. 专利数据为未来的mAb配方策略提供了早期见解.
科学领域:
- 生物制药配方 生物制药配方
- 药物输送系统 药物输送系统
- 蛋白质化学 蛋白质化学
背景情况:
- 单克隆抗体 (mAbs) 是重要的治疗药物,但面临着配方挑战,特别是高度和皮下输送.
- 辅助剂的选择对于mAb的稳定性和疗效至关重要,但对各种数据源的系统分析是有限的.
研究的目的:
- 利用已上市产品和专利数据,调查单克隆抗体 (mAb) 配方和辅助剂选择的趋势.
- 确定配方因素 (如度,途径) 与特定辅助剂选择之间的关联.
主要方法:
- 来自Drugs@FDA,CAS配方和Derwent创新数据库的综合数据 (截至2024年12月31日).
- 分析了108种已销售的mAb产品和6119项专利记录,涵盖388种已获得专利和141种已销售的配方.
- 利用比例测试来评估配方参数与辅助剂使用之间的关联.
主要成果:
- 发现抗体度与西司丁/酸使用之间存在显著的关联 (p<0.05).
- 服用途径影响了辅助剂的选择,特别是氨酸酶 (p<0.05).
- 高度和皮下配方偏好特定的辅助剂,如胺,氨酸和氨酸酶,而静脉注射配方使用酸盐/酸盐缓冲剂.
结论:
- 在mAb配方中的辅助剂选择受到抗体度和施用途径的显著影响.
- 糖是冷化配方中主要的冷保护剂,表面活性剂对于防止聚合至关重要.
- 专利数据可以信号新兴的配方策略,保证进一步调查的预测价值.
关键词:
单克隆抗体是一种单克隆抗体.这是一种依赖于度的度.辅助剂的选择 辅助剂的选择辅助剂的发展趋势mAb配方的不同形式.patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent监管洞察力 监管洞察力 监管洞察力通过皮下输送进行皮下输送.更多相关视频
04:24Author Spotlight: Advancing Biotherapeutic Mass Calculation by Introducing mAbScale, a Python-Based Desktop Application
Published on: June 16, 2023
2.2K
16:07Determination of the Relative Potency of an Anti-TNF Monoclonal Antibody mAb by Neutralizing TNF Using an In Vitro Bioanalytical Method
Published on: September 16, 2017
9.6K
相关概念视频
01:28Drug Products: Biologics, Biosimilars and Interchangeables
223
Body:Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
223
01:27Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
142
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
142
01:26Therapeutic Drug Monitoring: Drug Analysis Methods
171
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood or body tissues to tailor drug therapy effectively. This monitoring is critical for managing drugs with narrow therapeutic indices like digoxin and phenytoin, ensuring they are both safe and effective. For instance, monitoring theophylline levels in asthma patients involves precision and sensitivity to adjust doses according to individual responses to therapy, ensuring efficacy and...
171
01:29Clinically Relevant Drug Product Specifications: Methods of Establishment
195
Product specifications define the acceptable quality of a pharmaceutical product by ensuring identity, purity, potency, and strength. These specifications serve as benchmarks during development, manufacturing, and post-approval quality control. Clinically relevant specifications are particularly important because they directly relate to a drug's safety and efficacy in clinical use.Dissolution studies are critical biopharmaceutic tools that link in vitro behavior to in vivo performance. They...
195
01:22Biopharmaceutical Factors Influencing Drug Product Design: Overview
227
Rational drug product design integrates knowledge of the drug’s physicochemical properties, formulation components, manufacturing techniques, and intended route of administration. Each factor influences the drug’s performance, including how it is released, absorbed, and eliminated in the body.The physicochemical properties of a drug—such as solubility, stability, and particle size—affect its compatibility with excipients and the choice of dosage form. Excipients, though...
227
01:31Hybridoma Technology
17.2K
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
17.2K